Moderate to Severe Plaque Psoriasis Clinical Trials

79 clinical trials for Moderate to Severe Plaque Psoriasis across international registries, including 9 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis — RECRUITING · PHASE3
• A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis — RECRUITING · PHASE3
• A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab) — RECRUITING · PHASE1
• A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis — RECRUITING · PHASE3
• An Extension Study in Patients with Moderate to Severe Plaque Psoriasis to Evaluate the Long-term Safety, Efficacy and Durability of Response to ESK-001 (ONWARD3) — RECRUITING · PHASE3
• A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase Ⅲ Study to Evaluate the Efficacy and Safety of WD-890 Tablets for the Treatment of Moderate to Severe Plaque Psoriasis — RECRUITING · PHASE3
• A Study to Evaluate Effectiveness and Safety of a TYK2 Inhibitor in Subjects With Moderate to Severe Plaque Psoriasis — RECRUITING · NA
• Phase IV Study: Vunakizumab Efficacy and Safety in Moderate-to-severe Plaque Psoriasis — RECRUITING
• Real-World Safety and Effectiveness of Sotyktu (Deucravacitinib) in Patients With Moderate-to-Severe Plaque Psoriasis in Korea — RECRUITING
• A Phase 3 Study in Moderate to Severe Psoriasis Patients — COMPLETED · PHASE3
• Phase II study to assess the safety and efficacy of LNPP1955 in patients with psoriasis — COMPLETED · PHASE2
• A study to evaluate the efficacy and safety of Apremilast, Etanercept and placebo, in subjects with moderate to severe plaque psoriasis — COMPLETED · PHASE3
• A Phase 3 Study in Moderate to Severe Psoriasis Patients — COMPLETED · PHASE3
• Evaluating the benefits of using secukinumab rather than standard treatments as the first systemic treatment in moderate to severe psoriasis — COMPLETED · PHASE4
• A Phase 3, Multicenter, Randomized Study Comparing CNTO 1275 and Etanercept for the Treatment of Moderate to Severe Plaque Psoriasis — COMPLETED · PHASE3
• A Study to Test the Effect and Safety of Brodalumab Compared With Placebo and the Results of Stopping and Restarting Brodalumab Treatment in People with Moderate to Severe Plaque Psoriasis: AMAGINE-1 — TERMINATED · PHASE3
• A Study of Dose Optimization of Infliximab in the Treatment of Moderate to Severe Plaque Psoriasis. — COMPLETED · PHASE3
• A study in which patients suffering from moderate-to-severe psoriasis are assigned by chance, with neither the patient nor the doctor knowing the identity of the treatment in a given patient, to either the investigational drug CF101 or a matching dummy tablet, and are observed for beneficial and side effects. — COMPLETED · PHASE3
• A study with IMO-8400 in Patients with Moderate to Severe Psoriasis — COMPLETED · PHASE2
• A Phase 2 Study of HS-20118 to Evaluate the Efficacy and Safety in Participant With Moderate-to-Severe Plaque Psoriasis — NOT_YET_RECRUITING · PHASE2
• A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents From 6 Years to Less Than 18 Years of Age With Moderate to Severe Plaque Psoriasis — ACTIVE_NOT_RECRUITING · PHASE3
• A Study to Assess the Pharmacokinetics, Safety, and Efficacy of Two Doses of Bimekizumab in Adolescent Study Participants With Moderate to Severe Plaque Psoriasis — COMPLETED · PHASE2
• A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis — ACTIVE_NOT_RECRUITING · PHASE3
• A Phase 3, Multicenter, Open-Label Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of TAK-279 in Subjects with Moderate-to-Severe Plaque Psoriasis — TERMINATED · PHASE3
• A Multicenter, Randomized, Double-Blind Placebo-Controlled Phase 3 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Deucravacitinib in Adolescent Subjects (12 years to less than 18 years) with Moderate to Severe Plaque Psoriasis — TERMINATED · PHASE3
• A Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Dose-Range Finding Study of ORKA-001 in Participants with Moderate-to-Severe Plaque Psoriasis — TERMINATED · PHASE2
• A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment — TERMINATED · PHASE3
• A Phase 3b/4 Multi-center, Randomized, Open-label, Long-term Safety Study of Deucravacitinib in Comparison to Ustekinumab in Participants with Moderate-to-Severe Plaque Psoriasis (PRAGMATYK) — TERMINATED · PHASE3
• A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis — COMPLETED · PHASE3
• Metformin Combined With Secukinumab for Moderate-to-Severe Plaque Psoriasis in Overweight or Obese Chinese Patients — NOT_YET_RECRUITING · PHASE4
• A Phase 3, Randomized, Multicenter, Double-Blind Trial to Evaluate the Efficacy, Safety, and Tolerability of Zasocitinib (TAK-279) Compared to Deucravacitinib in Participants With Moderate-to-Severe Plaque Psoriasis — OTHER · PHASE3
• A MULTICENTER, RANDOMIZED, PARALLEL-GROUP, DOUBLE-BLIND, ACTIVE-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BIMEKIZUMAB COMPARED TO USTEKINUMAB IN CHILDREN AND ADOLESCENT FROM 6 YEARS TO LESS THAN 18 YEARS OF AGE WITH MODERATE TO SEVERE PLAQUE PSORIASIS — TERMINATED · PHASE3
• A Clinical Study Evaluating the Efficacy and Safety of CMS-D001 Tablets in the Treatment of Adult Patients With Moderate to Severe Plaque-type Psoriasis — NOT_YET_RECRUITING · PHASE2
• A Phase I Clinical Trial of Single Subcutaneous Injection or Intravenous Infusion of SHR-1139 Injection in Healthy Chinese Subjects and Multiple Subcutaneous Injections in Patients With Moderate-to-severe Plaque Psoriasis — COMPLETED · PHASE1
• To Assess the Effect of SCD-044 Treatment on Moderate to Severe Plaque Psoriasis — COMPLETED · PHASE2
• Secukinumab Drug Survival, Effectiveness and Tolerability in Pediatric Patients With Psoriasis — ACTIVE_NOT_RECRUITING
• A Phase 3, Randomized, Multicenter, Double-Blind, Placebo- and Active Comparator-Controlled Study With a Randomized Withdrawal and Retreatment Period to Evaluate the Efficacy, Safety, and Tolerability of TAK-279 in Subjects With Moderate-to-Severe Plaque Psoriasis — OTHER · PHASE3
• A Multicenter, Randomized, Double-Blind, Placebo and Active Comparator Controlled Phase 3 Study to Evaluate the Efficacy and Safety of ESK-001 in Patients with Moderate to Severe Plaque Psoriasis (ONWARD1) — OTHER · PHASE3
• A Phase 3, Randomized, Multicenter, Double-Blind, Placebo- and Active Comparator-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-279 in Subjects with Moderate-to-Severe Plaque Psoriasis — OTHER · PHASE3
• 2 Years Prospective Study to Collect Real-life Data on the Retention, Quality of Life, Effectiveness and Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis — COMPLETED
• A Multicenter, Randomized, Double-Blind, Placebo and Active Comparator Controlled Phase 3 Study in Patients with Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001 (ONWARD2) — OTHER · PHASE3
• An Open-Label, Multi-Center Extension Study to Characterize the Long-Term Safety and Efficacy of BMS-986165 in Subjects with Moderate-to-Severe Plaque Psoriasis — OTHER · PHASE3
• A Trial Comparing SHR-1139 Injection With Placebo in Patients With Moderate-to-severe Plaque Psoriasis — ACTIVE_NOT_RECRUITING · PHASE2
• A Study to Compare SB17 (Proposed Ustekinumab Biosimilar) to Stelara® in Subject With Moderate to Severe Plaque Psoriasis — COMPLETED · PHASE3
• A Phase III Study of SYHX1901 Tablets in the Treatment of Moderate to Severe Plaque Psoriasis — NOT_YET_RECRUITING · PHASE3
• A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Korean Study Participants With Moderate to Severe Plaque Psoriasis — COMPLETED · PHASE3
• Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ICP-488 in Patients with Moderate to Severe Plaque Psoriasis — COMPLETED · PHASE2
• A Study of HS-20137 in Participants with Moderate-to-severe Plaque Psoriasis — NOT_YET_RECRUITING · PHASE3
• A Multicenter, Open-Label, Randomized Study to Assess the Pharmacokinetics, Safety, and Efficacy of Two Doses of Bimekizumab in Adolescent Study Participants With Moderate to Severe Plaque Psoriasis — OTHER · PHASE2
• A Phase 2 Study of Jaktinib in Participants With Moderate to Severe Psoriasis — COMPLETED · PHASE2

Refine this search